12-week Randomized Study to Compare the Effect of Vildagliptin vs. Glibenclamide Associated to Metformin in Endothelial Function in Patients With Type 2 Diabetes and Hypertension

Trial Profile

12-week Randomized Study to Compare the Effect of Vildagliptin vs. Glibenclamide Associated to Metformin in Endothelial Function in Patients With Type 2 Diabetes and Hypertension

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Vildagliptin (Primary) ; Glibenclamide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 Primary endpoint has not been met. (Change from baseline in the reactive hyperemia index (RHI) after 12 weeks of vildagliptin x glibenclamide treatment) as per results presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
    • 15 Aug 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top